N/A
N=38
Ketamine Anesthesia in Electroconvulsive Therapy
Depression
Bottom Line
View on ClinicalTrials.gov: NCT01367119 ↗Enrolled (actual)
38
Serious AEs
0.0%
Results posted
Aug 2013
Primary outcome: Primary: Mean Depression Rating Using the Hospital Anxiety and Depression Scale (HADS) — 22.08; 24.45 units on a scale — p=0.171
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Ketamine (Drug); methohexital (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Mayo Clinic
- Primary completion
- Mar 2012
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mean Depression Rating Using the Hospital Anxiety and Depression Scale (HADS) |
22.08; 24.45 | 0.171 |
| SECONDARY Mean Depression Rating Using the Patient Health Questionnaire-9 (PHQ-9) |
15.98; 17.57 | 0.258 |
| SECONDARY Mean Post Anesthesia Recovery Side Effects |
0.12; 0.15; 0.29; 0.35; 0.07; 0.15 | 0.091 |
Summary
Does the use of ketamine as the anesthetic medication in electroconvulsive therapy (ECT) accelerate the antidepressant effect of ECT?
The study hypothesis was that depressed subjects receiving ECT with ketamine as the anesthetic agent would demonstrate a faster rate of improvement, defined as lower depression ratings after the second ECT than depressed patients receiving ECT with the usual anesthetic agent.
Eligibility Criteria
Inclusion criteria
- Diagnosis of depression, either unipolar or bipolar
- Subjects receiving ECT at the Mayo Clinic
Exclusion criteria
- Subjects not giving their own consent to ECT
- Subjects with schizophrenia, schizoaffective disorder, or dementia
- Subjects diagnosed with a major neurological disorder such as epilepsy, Parkinson disease, multiple sclerosis, or a neurodegenerative dementia.
Data sourced from ClinicalTrials.gov (NCT01367119). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.